A Phase 1-2 Dose-Escalation and Safety Study of ADXS-PSA Alone and of ADXS-PSA in Combination with KEYTRUDA®(MK-3475) in Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)